plerixafor has been researched along with Apoplexy in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Englund, E; Issazadeh-Navikas, S; Kuric, E; Liu, Y; Ruscher, K; Walter, HL; Wieloch, T | 1 |
| Chen, SC; He, QW; Hu, B; Huang, M; Huang, Y; Li, YN; Mao, L; Wang, MD; Xia, YP; Zheng, L | 1 |
| Chen, X; Kiesewetter, DO; Lu, J; Niu, G; Teng, G; Wang, Y; Wang, Z; Yue, X | 1 |
| Antunes, AR; Ruscher, K; van der Maten, G; Walter, HL; Wieloch, T | 1 |
| Cao, Y; Jolkkonen, J; Li, Y; Qu, H; Xiao, T; Zhao, C; Zhao, M; Zhao, S; Zhao, Y | 1 |
| Bae, E; Chen, CT; Kuan, HH; Shia, KS; Song, JS; Wang, Y; Wu, CH; Wu, KJ; Yeh, KC; Yu, SJ | 1 |
6 other study(ies) available for plerixafor and Apoplexy
| Article | Year |
|---|---|
Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke.
Topics: Animals; Atrophy; Benzylamines; Blotting, Western; Brain; Brain Ischemia; Chemokine CXCL12; Cyclams; DNA; DNA Fragmentation; Down-Regulation; Environment; Flow Cytometry; Fluorescent Antibody Technique; Heterocyclic Compounds; Immunohistochemistry; Ischemic Attack, Transient; Male; Middle Cerebral Artery; Rats; Rats, Inbred SHR; Receptors, CXCR4; Recovery of Function; Signal Transduction; Spleen; Stroke | 2013 |
Endogenous endothelial progenitor cells participate in neovascularization via CXCR4/SDF-1 axis and improve outcome after stroke.
Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Brain; Brain Ischemia; Capillaries; Cerebrovascular Circulation; Chemokine CXCL12; Cyclams; Disease Models, Animal; Endothelial Progenitor Cells; Heterocyclic Compounds; Infarction, Middle Cerebral Artery; Male; Neovascularization, Physiologic; Rats, Sprague-Dawley; Receptors, CXCR4; Severity of Illness Index; Stroke | 2014 |
[(18)F]DPA-714 PET imaging of AMD3100 treatment in a mouse model of stroke.
Topics: Animals; Benzylamines; Cyclams; Disease Models, Animal; Fluorine Radioisotopes; Heterocyclic Compounds; Male; Mice; Mice, Inbred BALB C; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Stroke | 2014 |
Treatment with AMD3100 attenuates the microglial response and improves outcome after experimental stroke.
Topics: Animals; Benzylamines; Brain Infarction; Calcium-Binding Proteins; Cyclams; Cytokines; Disease Models, Animal; Gene Expression Regulation; Green Fluorescent Proteins; Heterocyclic Compounds; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Microglia; Microscopy, Confocal; Nervous System Diseases; Neuroprotective Agents; Photons; Receptors, Interleukin-8A; Recovery of Function; Stroke | 2015 |
CXCR4 antagonist AMD3100 reverses the neurogenesis and behavioral recovery promoted by forced limb-use in stroke rats.
Topics: Animals; Benzylamines; Brain; Brain Ischemia; Central Nervous System Agents; Chemokine CXCL12; Cyclams; Disease Models, Animal; Doublecortin Protein; Endothelin-1; Forelimb; Heterocyclic Compounds; Immobilization; Male; Maze Learning; Motor Activity; Musculoskeletal Manipulations; Neurogenesis; Neurons; Random Allocation; Rats, Wistar; Receptors, CXCR4; Recovery of Function; Stroke; Stroke Rehabilitation | 2015 |
A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Benzylamines; Brain; Brain Infarction; Chemotaxis; Cyclams; HEK293 Cells; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Interleukin-6; Male; Mice, Inbred C57BL; Neurons; Neuroprotection; Neuroprotective Agents; Quinazolines; Rats, Sprague-Dawley; Receptors, CXCR4; Stroke; Triazoles; Tumor Necrosis Factor-alpha | 2017 |